Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known coronary artery disease who presented with and ACS and underwent PCI.~* Age between 18 and 74 years old.~* On therapy with low-dose aspirin (81 mg) and prasugrel 10 mg/daily for at least 14 days as per standard of care~Exclusion criteria:~* History of stroke, transient ischemic attack (TIA) or intracranial bleeding.~* Known allergies to ticagrelor.~* Weight \< 60 Kg~* On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban).~* Treatment with IIb/IIIa glycoprotein inhibitors in the last 7 days.~* Blood dyscrasia or bleeding diathesis.~* Platelet count \<80x106/mL.~* Hemoglobin \<10 g/dL.~* Active bleeding.~* Hemodynamic instability.~* Creatinine Clearance \<30 mL/minute.~* Known severe hepatic dysfunction.~* Patients with sick sinus syndrome (SSS) or high degree atrio-ventricular block without pacemaker protection.~* Current treatment with drugs interfering with cytochrom P450 3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromycin.~* Pregnant females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor 180mg (Type: EXPERIMENTAL): Patients on prasugrel will switch to ticagrelor with a 180mg loading dose
- Ticagrelor 90mg (Type: EXPERIMENTAL): Patients on prasugrel will switch to ticagrelor with a 90mg maintenance dose
- Prasugrel 10mg (Type: ACTIVE_COMPARATOR): Patients already on prasugrel, will maintain prasugrel

Based on this trial design, predict the completion outcome and termination type (if applicable).